Literature DB >> 1631945

Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation.

N Perico1, P Ruggenenti, F Gaspari, L Mosconi, A Benigni, C S Amuchastegui, F Gasparini, G Remuzzi.   

Abstract

A variety of side effects are associated with the use of cyclosporine, the most relevant of which remains the renal toxicity. We did parallel studies on cyclosporine pharmacokinetics and renal function in patients who had a recent kidney transplant and were given cyclosporine as a part of their immunosuppressive therapy. Seven consecutive renal transplant patients were studied at the end of a month of treatment while on different oral cyclosporine doses (5, 3.5, 2.5, or 1.5 mg/kg, twice a day, respectively). Cyclosporine pharmacokinetics profiles and renal function parameters (GFR and renal plasma flow [RPF], as inulin and p-amino hippurate clearances, respectively) were determined before and over a 12-hr period after each single dose of cyclosporine. Plasma levels and urinary excretion rate of endothelin were also studied before and after the highest cyclosporine dose (5 mg/kg). Mean trough levels, area under the curve values, and maximum concentration of blood cyclosporine were comparable after 5 and 3.5 mg/kg cyclosporine and decreased in a dose-dependent manner after the lower doses (2.5 and 1.5 mg/kg). In the same patients GFR declined on average 63%, 53%, 35%, and 18%, 2-4 hr after maximum cyclosporine concentration was reached. As blood levels of cyclosporine returned to trough, GFR progressively increased to baseline. Similar results were found for RPF; 5 mg/kg cyclosporine did not modify endothelin plasma levels. By contrast, urinary excretion of the peptide increased significantly (P less than 0.01) in the 6 hr that followed cyclosporine administration and returned within the normal range in the subsequent 6 hr. Following each oral administration of cyclosporine, 2-4 hr after peak blood concentration was reached, patients showed renal hypoperfusion, transient and rapidly reversible. This was associated with an increased urinary endothelin excretion rate that was also transient. It is speculated that an excessive renal synthesis of endothelin is the cause of the daily renal hypoperfusion observed in patients with renal transplants given cyclosporine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1631945     DOI: 10.1097/00007890-199207000-00009

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A.

Authors:  D D Ankola; A Battisti; R Solaro; M N V Ravi Kumar
Journal:  J R Soc Interface       Date:  2010-05-26       Impact factor: 4.118

Review 2.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

Review 3.  Cyclosporin-induced hypertension: incidence, pathogenesis and management.

Authors:  S J Taler; S C Textor; V J Canzanello; L Schwartz
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

4.  Cyclosporine-induced transient renal hypoperfusion in adolescent transplant recipients.

Authors:  L Dello Strologo; L Massella; G Rizzoni
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

Review 5.  Role of hypertension in kidney transplant recipients.

Authors:  Charalampos Loutradis; Pantelis Sarafidis; Smaragdi Marinaki; Miriam Berry; Richard Borrows; Adnan Sharif; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2021-05-04       Impact factor: 3.012

Review 6.  Transplant renal artery stenosis: clinical manifestations, diagnosis and therapy.

Authors:  Wei Chen; Liise K Kayler; Martin S Zand; Renu Muttana; Victoria Chernyak; Graciela O DeBoccardo
Journal:  Clin Kidney J       Date:  2014-12-09

7.  A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.

Authors:  Jeffrey S Zaltzman; Vesta Lai; Miklos Z Schulz; Kyung-Hee Moon; David Z Cherney
Journal:  Transpl Int       Date:  2014-09-29       Impact factor: 3.782

Review 8.  When is contrast-enhanced sonography preferable over conventional ultrasound combined with Doppler imaging in renal transplantation?

Authors:  Markus Zeisbrich; Lars P Kihm; Felix Drüschler; Martin Zeier; Vedat Schwenger
Journal:  Clin Kidney J       Date:  2015-08-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.